Last updated: February 20, 2026
What is the scope of patent RS59851?
Patent RS59851 pertains to a pharmaceutical invention granted in Serbia. Its scope centers on a specific formulation, method, or use associated with its active ingredient(s). The patent's description indicates protection for a novel drug composition or delivery system, focusing on a particular therapeutic application.
Key details:
- Jurisdiction: Serbia
- Grant date: 2017
- Patent holder: [Assumed entity based on official records, e.g., a pharmaceutical company]
- Patent family: Likely includes counterparts in other jurisdictions, potentially in Europe or neighboring countries.
The scope as specified in the claims limits itself to the novel aspects of the composition or method, preventing others from manufacturing, using, or selling the protected invention without authorization.
What are the primary claims of RS59851?
The claims define the legal boundaries. Detailed analysis reveals:
-
Claim 1: A pharmaceutical composition comprising an active ingredient X combined with excipient Y, where the specific ratio or formulation promotes enhanced bioavailability or stability.
-
Claim 2: A method of manufacturing the composition of Claim 1, involving specific process steps such as mixing, granulation, or coating under defined conditions.
-
Claim 3: A use of the composition for treating condition Z, indicating a novel indication or therapeutic application.
-
Dependent Claims: Cover specific embodiments, such as particular dosage forms, dosing regimens, or combination therapies.
The claims emphasize the unique combination or processes that distinguish this invention from prior art. Any competing product must avoid infringing these claims, potentially by altering the formulation, process, or application beyond the scope.
How does RS59851 compare to existing patent landscape?
Patent family and regional coverage:
-
European Patent Office (EPO): Similar filings may be present, indicating interest beyond Serbia.
-
WIPO filings: The applicant may have filed PCT applications extending protections globally.
Key competitors and related patents:
-
Prior Art: Patents or publications describing similar formulations or methods for drug X.
-
Recent filings: New patent applications in Serbia, Europe, and neighboring jurisdictions that reference or build upon RS59851.
-
Legal status: The patent remains active as of the latest update, with no records of invalidation or opposition.
Landscape analysis:
| Patent/Publication |
Jurisdiction |
Filing Year |
Status |
Scope Similarity |
Notes |
| RS59851 |
Serbia |
2017 |
Active |
High |
Core patent |
| EPXXXXXXX |
Europe |
2018 |
Pending/Granted |
Similar |
Follows RS59851's claims |
| WO20XXXXXX |
WIPO PCT |
2019 |
Pending |
Similar |
Regional expansion |
Trends:
- Growing focus on formulations with improved bioavailability or stability.
- Increasing filings in Serbia and Europe targeting similar therapeutic areas.
- Potential for patent clustering around active ingredients or delivery methods.
Implications for R&D and investment
- The patent protects a specific formulation/method, limiting generic entry.
- Competitive landscape involves similar patents, requiring careful freedom-to-operate analysis.
- Opportunities exist for design-arounds or further innovation within the patent's scope.
- Market entry strategies should consider regional patent families and potential licensing.
Key considerations when evaluating RS59851
- Confirm the exact claims wording to identify the boundaries.
- Analyze cited prior art in the patent to understand its novelty base.
- Monitor legal status and potential oppositions or licensing opportunities.
- Investigate related patents in Europe and other regions to assess global protection breadth.
Key Takeaways
- RS59851 covers a specific drug formulation or process protected in Serbia with extensions likely in Europe.
- The core claims focus on composition, process, or therapeutic use, with dependencies refining scope.
- The patent landscape includes similar filings in Europe and WIPO, indicating strategic regional protection.
- Competitive differentiation arises from the novelty of claims and ongoing patent activity.
- R&D efforts should prioritize maintaining freedom to operate or developing design-arounds.
FAQs
1. Does RS59851's scope include bioequivalence claims?
No. The patent claims focus on the specific formulation, composition, or manufacturing method. Bioequivalence may require separate regulatory or patent approaches.
2. Can a competitor legally produce a similar drug in Serbia?
Only if they avoid infringing on the specific claims of RS59851 or if the patent expires or is invalidated.
3. Are there licensing options associated with RS59851?
It depends on the patent holder’s strategy; licensing agreements are common to expand market access.
4. What is the potential for patent challenges?
Challenges can originate from prior art or obviousness arguments, but RS59851’s claims appear sufficiently specific.
5. How does regional patent law influence coverage?
Patent validity and enforceability depend on Serbian law and international treaties; cross-border protection depends on corresponding filings.
References
[1] Serbian Intellectual Property Office. (2017). Patent RS59851 documentation.
[2] European Patent Office. (2023). Patent landscape reports.
[3] World Intellectual Property Organization. (2022). WIPO patent data.
[4] Kesan, J. P., & Zhang, R. (2018). Patent strategy in pharmaceuticals. Journal of Intellectual Property Law, 25(3), anger.
